Glenmark Pharmaceuticals has announced that the United States Food and Drug Administration (US FDA) conducted a Good Manufacturing Practices (GMP) inspection at its manufacturing facility in Goa between June 22-30, 2026.

At the conclusion of the inspection, the US FDA issued the company a Form 483 containing six observations. Glenmark clarified that none of the observations relate to data integrity issues and that there were no repeat observations from previous inspections.

According to the company, the observations are procedural in nature and do not affect the quality or supply of its commercial products. Glenmark stated that it does not anticipate any disruption to the manufacturing or distribution of products from the Goa facility as a result of the inspection findings.

The company further said it will work closely with the US FDA to address all the observations and submit a comprehensive response within the stipulated regulatory timeline.

The inspection forms part of the US FDA's routine regulatory oversight of pharmaceutical manufacturing facilities to ensure compliance with current Good Manufacturing Practices (cGMP). Glenmark reiterated its commitment to maintaining high standards of quality, compliance and regulatory excellence across its manufacturing operations.